TMCI

Treace Medical Concepts' stock (TMCI) has declined significantly in the past six months. In Q1 2026, the company reported a loss of $0.28 per share, beating estimates, with revenue of $47.2 million, exceeding expectations but declining 10% year-over-year due to a shift towards lower-priced minimally invasive products and reduced sales of bunion procedure kits. Management reaffirmed its full-year 2026 revenue guidance of $202 million to $212 million, expecting revenue declines to continue until the fourth quarter, with growth returning due to accelerating case volumes, the anniversary of the product mix shift, and contributions from planned 2026 product launches. New product innovations launched in 2025 and planned launches in 2026 are central to its growth strategy.